We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesMereo BioPharma Group PLC ADR

Mereo BioPharma Group PLC ADR

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.2961 USD -0.01 ( 3.42%)
Last update at 2026-11-12T15:44:00Z
VOLUME
143756
Market Cap
469.91M

Momentum Score

…

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.29
Low
0.31
High
52 Week Price Range
0.99
Low
4.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mereo BioPharma Group plc is a small clinical-stage biopharmaceutical company that acquires and develops therapeutics for oncology and rare diseases through in-licensing, clinical development and partnering. Long-term growth may be driven by positive clinical trial results, regulatory approvals and successful partnering or commercialization of pipeline assets, which could support upside if programs advance.

Material risks include clinical and regulatory setbacks, limited or no product revenue requiring additional financing, patent and competitive pressures, and operational or liquidity constraints that could delay or dilute development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.31
Dividend Yield
-
Revenue TTM
10.00M
Revenue Per Share
0.07
Gross Profit TTM
0.94M
Debt / Equity
0.12
ROE
-55.90%
Net Debt
-51.47M
ROCE
-76.42%
Diluted EPS TTM
-0.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.09M 14.24M -166.45M -41.12M -37.31M
Minority interest - - - - 0.00M
Net income -34.20M 12.72M -163.63M -34.84M -32.03M
Selling general administrative 19.54M 15.93M 21.22M 15.91M 12.50M
Gross profit 2.44M 18.56M -15.95M -23.73M -22.70M
Reconciled depreciation 0.73M 0.64M 1.60M 1.58M 0.04M
Ebit -43.57M -20.94M -37.57M -39.52M -34.90M
Ebitda -42.06M -20.31M -37.52M -37.56M -34.86M
Depreciation and amortization 1.51M 0.62M 0.04M 1.95M 0.04M
Non operating income net other - - - - 0.00M
Operating income -43.57M -20.94M -37.57M -39.52M -35.21M
Other operating expenses 43.57M 57.40M 37.57M 39.52M 35.21M
Interest expense 3.36M 4.00M 6.38M 3.50M 2.36M
Tax provision -1.90M 1.52M -2.82M -6.27M -5.28M
Interest income 0.70M 0.00M 0.01M 0.18M 0.31M
Net interest income -2.67M -4.02M -6.34M -3.58M -2.03M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense -1.90M 1.52M -2.82M -6.27M -5.28M
Total revenue 1.51M 36.46M 0.39M -0.12M 0.00M
Total operating expenses 44.51M 39.49M 21.22M 15.91M 12.50M
Cost of revenue -0.94M 17.91M 16.35M 23.61M 22.70M
Total other income expense net 7.48M 35.18M -128.88M -1.60M -0.04M
Discontinued operations - - - - 0.00M
Net income from continuing ops -34.20M 12.72M -163.63M -34.84M -32.03M
Net income applicable to common shares -34.20M 12.72M -163.63M -34.84M -32.03M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 66.50M 88.08M 126.42M 62.95M 86.45M
Intangible assets 1.09M 24.12M 24.56M 31.65M 44.46M
Other current assets 1.36M - 3.21M 2.03M 2.40M
Total liab 15.96M 26.21M 38.41M 77.92M 46.19M
Total stockholder equity 50.54M 61.87M 88.00M -14.97M 40.26M
Other current liab 0.03M 10.05M 1.27M 4.60M 0.35M
Common stock 2.77M 1.88M 1.75M 1.02M 0.29M
Capital stock 2.77M 1.88M 1.75M 1.02M 0.29M
Retained earnings -419.63M -331.16M -296.97M -309.69M -146.06M
Other liab - 0.31M 9.74M 52.05M 1.62M
Cash 57.42M 56.33M 94.30M 23.47M 16.35M
Total current liabilities 9.49M 24.68M 12.54M 8.56M 29.88M
Current deferred revenue 6.46M - 8.37M - 5.45M
Net debt -51.47M -43.56M -77.54M -5.53M 16.07M
Short term debt 0.65M 11.55M 0.62M 0.64M 17.73M
Short long term debt - 11.09M - - 15.14M
Short long term debt total 5.95M 12.77M 16.76M 17.94M 32.42M
Other stockholder equity 484.88M 253.25M 246.32M 160.48M 138.71M
Property plant equipment - 1.83M 2.53M 1.57M 11.56M
Total current assets 63.76M 62.13M 99.32M 29.73M 30.43M
Net tangible assets - 37.75M 63.44M -46.62M -4.20M
Short term investments - - - - 0.00M
Net receivables 3.73M 2.67M 1.82M 4.64M 11.98M
Long term debt 4.39M - 14.38M 16.14M 5.37M
Inventory 1.25M - - - -
Accounts payable 2.35M 3.08M 2.29M 3.33M 6.35M
Accumulated other comprehensive income -17.48M 137.91M 136.90M 133.22M 47.32M
Common stock total equity - - - 1.02M 0.29M
Non currrent assets other - - - - 11.56M
Non current assets total 2.74M 25.95M 27.09M 33.22M 56.01M
Capital lease obligations 1.56M 1.69M 2.38M 1.79M 11.90M
Long term debt total - - - - 14.69M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1.50M -0.42M 1.50M 43.30M 0.25M
Change to liabilities 1.13M -1.26M -3.55M -6.73M 1.60M
Total cashflows from investing activities - -0.42M 1.50M 43.30M 0.25M
Net borrowings -0.94M -0.69M 22.49M -2.21M 0.46M
Total cash from financing activities -0.78M 77.65M 34.74M -5.71M -2.07M
Change to operating activities - - - - 0.00M
Net income -36.09M 14.24M -166.45M -41.12M -37.31M
Change in cash -37.96M 70.83M 7.12M -8.70M -25.00M
Begin period cash flow 94.30M 23.47M 16.35M 25.04M 50.04M
End period cash flow 56.33M 94.30M 23.47M 16.35M 25.04M
Total cash from operating activities -38.82M -5.24M -28.34M -45.93M -23.14M
Issuance of capital stock 0.00M 78.53M 20.14M 0.00M 0.27M
Depreciation 0.73M 0.64M 1.60M 1.58M 0.04M
Other cashflows from investing activities - 0.00M 0.04M 0.38M 0.29M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - - - - 0.00M
Change to account receivables 0.69M -0.59M 0.14M -0.94M 7.20M
Sale purchase of stock - 0.00M 0.00M -1.00M -0.31M
Other cashflows from financing activities 0.15M -0.19M 36.49M -2.50M -2.04M
Change to netincome - -16.76M 137.10M -5.00M 6.45M
Capital expenditures 0.01M 0.54M 0.02M 0.02M 0.04M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital 1.82M -1.84M -3.41M -7.67M 2.41M
Stock based compensation 3.86M 3.30M 1.56M 1.64M 2.19M
Other non cash items -9.14M 13.41M 5.22M -0.43M 1.92M
Free cash flow -38.83M -5.77M -28.36M -45.95M -23.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MREO
Mereo BioPharma Group PLC ADR		 -0.01
3.42%		 0.30 - - 38.15 7.55 33.00 -12.67
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Mereo BioPharma Group PLC ADR

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

One Cavendish Place, London, United Kingdom, W1G 0QF

44 33 3023 7300

https://www.mereobiopharma.com

33

Name Title Year Born
Dr. Denise Scots-Knight Ph.D. Co-Founder, CEO & Exec. Director 1959
Mr. Charles Sermon Co-Founder, Gen. Counsel & Company Sec. 1969
Dr. Alastair MacKinnon M.D., MBBS Co-Founder and Chief of Portfolio & Pipeline Strategy 1970
Dr. John P. Richard M.B.A., MBA Co-Founder & Chief Bus. Officer 1957
Ms. Christine Fox CPA Chief Financial Officer 1981
Dr. John A. Lewicki Ph.D. Chief Scientific Officer 1952
Dr. Jackie Parkin Therapy Area Head of Respiratory Endocrinology NA
Ms. Alexandra Hughes-Wilson Chief of Patient Access & Commercial Planning 1971
Dr. Suba Krishnan Sr. VP of Clinical Devel. NA
Dr. Fiona Bor Head of Intellectual Property NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…